Acute Exacerbation and Longitudinal Lung Function Change of Preserved Ratio Impaired Spirometry

References

• Wan ES, Fortis S, Regan EA, et al. Longitudinal phenotypes and mortality in preserved ratio impaired spirometry in the copdgene study. Am J Respir Crit Care Med. 2018;198:1397–1405. doi:10.1164/rccm.201804-0663OC
   PubMed Web of Science ®Google Scholar
• Wan ES, Hokanson JE, Murphy JR, et al. Clinical and radiographic predictors of GOLD–unclassified smokers in the COPDGene study. Am J Respir Crit Care Med. 2011;184(1):57–63. doi:10.1164/rccm.201101-0021OC
   PubMed Web of Science ®Google Scholar
• Wan ES, Castaldi PJ, Cho MH, et al. Epidemiology, genetics, and subtyping of preserved ratio impaired spirometry (PRISm) in COPDGene. Respir Res. 2014;15:89. doi:10.1186/s12931-014-0089-y
   PubMed Web of Science ®Google Scholar
• Higbee DH, Granell R, Davey Smith G, Dodd JW. Prevalence, risk factors, and clinical implications of preserved ratio impaired spirometry: a UK Biobank cohort analysis. Lancet Respir Med. 2022;10:149–157. doi:10.1016/S2213-2600(21)00369-6
   PubMed Web of Science ®Google Scholar
• Wijnant SRA, De Roos E, Kavousi M, et al. Trajectory and mortality of preserved ratio impaired spirometry: the Rotterdam study. Eur Respir J. 2020;2020:55.
   Google Scholar
• Sood A, Petersen H, Qualls C, et al. Spirometric variability in smokers: transitions in COPD diagnosis in a five-year longitudinal study. Respir Res. 2016;17:147. doi:10.1186/s12931-016-0468-7
   PubMed Web of Science ®Google Scholar
• Jankowich M, Elston B, Liu Q, et al. Restrictive spirometry pattern, cardiac structure and function, and incident heart failure in African Americans. The Jackson heart study. Ann Am Thorac Soc. 2018;15:1186–1196. doi:10.1513/AnnalsATS.201803-184OC
   PubMed Web of Science ®Google Scholar
• Woodruff PG, Barr RG, Bleecker E, et al. Clinical significance of symptoms in smokers with preserved pulmonary function. N Engl J Med. 2016;374:1811–1821. doi:10.1056/NEJMoa1505971
   PubMed Web of Science ®Google Scholar
• Washio Y, Sakata S, Fukuyama S, et al. Risks of mortality and airflow limitation in Japanese with preserved ratio impaired spirometry. Am J Respir Crit Care Med. 2022. doi:10.1164/rccm.202110-2302OC
   PubMed Web of Science ®Google Scholar
• Dransfield MT, Kunisaki KM, Strand MJ, et al. Acute exacerbations and lung function loss in smokers with and without chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2017;195:324–330. doi:10.1164/rccm.201605-1014OC
   PubMed Web of Science ®Google Scholar
• Charlson ME, Pompei P, Ales KL, MacKenzie CR. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis. 1987;40:373–383. doi:10.1016/0021-9681(87)90171-8
   PubMedGoogle Scholar
• Global Initiative for Chronic Obstructive Lung Disease. Global Strategy for the Diagnosis, Management, and Prevention of Chronic Obstructive Pulmonary Disease; 2023.
   Google Scholar
• Young KA, Strand M, Ragland MF, et al. Pulmonary subtypes exhibit differential global initiative for chronic obstructive lung disease spirometry stage progression: the COPDGene(R) study. Chronic Obstr Pulm Dis. 2019;6:414–429. doi:10.15326/jcopdf.6.5.2019.0155
   PubMed Web of Science ®Google Scholar
• Stolz D, Mkorombindo T, Schumann DM, et al. Towards the elimination of chronic obstructive pulmonary disease: a lancet commission. Lancet. 2022;400:921–972. doi:10.1016/S0140-6736(22)01273-9
   PubMed Web of Science ®Google Scholar
• McGuinness G, Naidich DP, Leitman BS, McCauley DI. Bronchiectasis: CT evaluation. AJR Am J Roentgenol. 1993;160:253–259. doi:10.2214/ajr.160.2.8424327
   PubMed Web of Science ®Google Scholar
• Rhee CK, Yoo KH, Lee JH, et al. Clinical characteristics of patients with tuberculosis-destroyed lung. Int J Tuberc Lung Dis. 2013;17:67–75. doi:10.5588/ijtld.12.0351
   PubMed Web of Science ®Google Scholar
• Hatabu H, Hunninghake GM, Richeldi L, et al. Interstitial lung abnormalities detected incidentally on CT: a position paper from the Fleischner Society. Lancet Respir Med. 2020;8:726–737. doi:10.1016/S2213-2600(20)30168-5
   PubMed Web of Science ®Google Scholar
• Donaldson GC, Seemungal TA, Bhowmik A, Wedzicha JA. Relationship between exacerbation frequency and lung function decline in chronic obstructive pulmonary disease. Thorax. 2002;57:847–852. doi:10.1136/thorax.57.10.847
   PubMed Web of Science ®Google Scholar
• Papi A, Vestbo J, Fabbri L, et al. Extrafine inhaled triple therapy versus dual bronchodilator therapy in chronic obstructive pulmonary disease (TRIBUTE): a double-blind, parallel group, randomised controlled trial. Lancet. 2018;391:1076–1084. doi:10.1016/S0140-6736(18)30206-X
   PubMed Web of Science ®Google Scholar
• Groenewegen KH, Schols AM, Wouters EF. Mortality and mortality-related factors after hospitalization for acute exacerbation of COPD. Chest. 2003;124:459–467. doi:10.1378/chest.124.2.459
   PubMed Web of Science ®Google Scholar
• Kim J, Yoon HI, Oh YM, et al. Lung function decline rates according to GOLD group in patients with chronic obstructive pulmonary disease. Int J Chron Obstruct Pulmon Dis. 2015;10:1819–1827. doi:10.2147/COPD.S87766
   PubMed Web of Science ®Google Scholar
• Strand M, Khatiwada A, Baraghoshi D, et al. Predicting COPD progression in current and former smokers using a joint model for forced expiratory volume in 1 second and forced expiratory volume in 1 second to forced vital capacity ratio. Chronic Obstr Pulm Dis. 2022;9:439–453. doi:10.15326/jcopdf.2022.0281
   PubMed Web of Science ®Google Scholar
• Marott JL, Ingebrigtsen TS, Colak Y, Vestbo J, Lange P. Trajectory of preserved ratio impaired spirometry: natural history and long-term prognosis. Am J Respir Crit Care Med. 2021;204:910–920. doi:10.1164/rccm.202102-0517OC
   PubMed Web of Science ®Google Scholar